layoffs
FDA Staffing Data Reveal Historic Departures in Fiscal 2025
FDA; staffing; departures; fiscal 2025; layoffs; regulatory impact; CDER; CBER; drug approval delays; organizational disruption
Galapagos Winds Down Cell Therapy Business After Failed Sale, Cuts 365 Jobs and Shutters Global Sites
Galapagos; cell therapy; exit; layoffs; restructuring; site closures
Ferring to Downsize by 500 Staffers in Global Reorganization Effort
Ferring; layoffs; staff reduction; optimisation programme; enterprise reorganization; pharma; headcount; workforce restructuring
Ferring Pharmaceuticals to Cut 500 Jobs in Global Restructuring Effort
Ferring Pharmaceuticals; Layoffs; Global Restructuring
Takeda to Cut 137 Staffers After Exiting Cell Therapy Research
Takeda; layoffs; cell therapy exit; biotech industry; restructuring; Massachusetts R&D; strategic portfolio reprioritization; pipeline shake-up
IO Biotech Sheds 50% of Staff After FDA Blocks Cancer Vaccine Approval Path
IO Biotech; layoffs; cancer vaccine; FDA rejection; Cylembio; Phase 3 trial; melanoma; regulatory setback; cost cutting; clinical trial
Biogen Shuffles Staff and Exits AAV Gene Therapy Programs After Strategic Shift
Biogen; AAV gene therapy; layoffs; staff reorganization; biotech layoffs; pharma restructuring; gene therapy discontinuation
Rising Pharmaceuticals Lowers Headcount After Closing Decatur Factories
Rising Pharmaceuticals; factory closure; Decatur Illinois; layoffs; pharma industry; WARN notice; 2025
Seres Therapeutics Cuts 25% of Workforce Following FDA Feedback on Microbiome Therapy Trial
Seres Therapeutics; layoffs; microbiome; FDA feedback; SER-155; phase 2 trial; workforce reduction; biopharma; clinical studies; cash runway
Pfizer and Arvinas Abandon Commercialization of PROTAC Inhibitor, Triggering Layoffs and Pipeline Refocus
Pfizer; Arvinas; PROTAC; vepdegestrant; layoffs; out-licensing; FDA; breast cancer; oncology; CDK inhibitors